Table 6 Adverse events of eptinezumab group versus placebo group on the basis of different eptinezumab doses subgroups.
From: Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment
Subgroups | Number of studies | Number of events/participants | I2(%) | Risk ratio(95%CI) | P | |
|---|---|---|---|---|---|---|
Eptinezumab group | Placebo group | |||||
1000 mg | 1 | 46/81 | 43/82 | N/A | 1.08 (0.82–1.43) | 0.58 |
300 mg | 4 | 508/989 | 490/1007 | 0 | 1.05 (0.97–1.15) | 0.23 |
100 mg | 5 | 519/1238 | 515/1249 | 0 | 1.01 (0.93–1.11) | 0.75 |
30 mg | 2 | 184/341 | 200/343 | 35 | 0.93 (0.81–1.06) | 0.26 |
10 mg | 1 | 74/130 | 68/121 | N/A | 1.01 (0.82–1.26) | 0.91 |
